Article Text

Download PDFPDF
Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin’s lymphoma: the survival gain improves as more mature follow-up data become available
  1. Andrea Messori1,
  2. Laura Bartoli1,
  3. Daniele Mengato2,3,
  4. Marco Chiumente3,4
  1. 1 HTA Unit, Regione Toscana, Firenze, Italy
  2. 2 Hospital Pharmacy, Bolzano Hospital, Bolzano, Italy
  3. 3 SIFACT, Italian Society of Clinical Pharmacy and Therapeutics, Milano, Italy
  4. 4 Scientific Direction, Milan, Italy
  1. Correspondence to Dr Andrea Messori, HTA Unit, Regione Toscana, Via Alderotti 26/N, 50135 Firenze, Italy;{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The TRANSCEND trial1 studied a cohort of more than 250 patients with relapsed/refractory non-Hodgkin's lymphoma treated with the chimeric antigen receptor T-cell (CART) product, lisocabtagene maraleucel. This trial enrolled a high number of patients and included a relatively long follow-up (36 months).

Estimating the gain in overall survival (OS) for CART patients versus non-CART controls suffers from the lack of long-term survival information for CART. One advantage of the TRANSCEND trial is the availability of survival results at 36 months; this allows us to reliably determine the survival gain. To carry out this estimation, we kept in mind that the restricted mean survival time (RMST) is recognised to be the best outcome measure for managing long-term …

View Full Text


  • Contributors AM and LB performed the analysis, DM and MC separately did the same analysis, and the results were compared. The four co-authors equally contributed to writing the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.